139 related articles for article (PubMed ID: 22458531)
21. A 4-deoxy analogue of N-acetyl-D-glucosamine inhibits heparan sulphate expression and growth factor binding in vitro.
van Wijk XM; Oosterhof A; van den Broek SA; Griffioen AW; ten Dam GB; Rutjes FP; van Delft FL; van Kuppevelt TH
Exp Cell Res; 2010 Sep; 316(15):2504-12. PubMed ID: 20433828
[TBL] [Abstract][Full Text] [Related]
22. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.
Joyce JA; Freeman C; Meyer-Morse N; Parish CR; Hanahan D
Oncogene; 2005 Jun; 24(25):4037-51. PubMed ID: 15806157
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88).
Karoli T; Liu L; Fairweather JK; Hammond E; Li CP; Cochran S; Bergefall K; Trybala E; Addison RS; Ferro V
J Med Chem; 2005 Dec; 48(26):8229-36. PubMed ID: 16366604
[TBL] [Abstract][Full Text] [Related]
24. The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action.
Weissmann M; Bhattacharya U; Feld S; Hammond E; Ilan N; Vlodavsky I
Matrix Biol; 2019 Apr; 77():58-72. PubMed ID: 30096360
[TBL] [Abstract][Full Text] [Related]
25. Antiangiogenic cancer therapy.
Cao Y
Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
[TBL] [Abstract][Full Text] [Related]
26. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
Edovitsky E; Elkin M; Zcharia E; Peretz T; Vlodavsky I
J Natl Cancer Inst; 2004 Aug; 96(16):1219-30. PubMed ID: 15316057
[TBL] [Abstract][Full Text] [Related]
27. Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation.
Brennan TV; Lin L; Brandstadter JD; Rendell VR; Dredge K; Huang X; Yang Y
J Clin Invest; 2016 Jan; 126(1):207-19. PubMed ID: 26649979
[TBL] [Abstract][Full Text] [Related]
28. Mammalian heparanase as mediator of tumor metastasis and angiogenesis.
Vlodavsky I; Elkin M; Pappo O; Aingorn H; Atzmon R; Ishai-Michaeli R; Aviv A; Pecker I; Friedmann Y
Isr Med Assoc J; 2000 Jul; 2 Suppl():37-45. PubMed ID: 10909416
[TBL] [Abstract][Full Text] [Related]
29. [Human heparanase: roles in invasion and metastasis of cancer].
Gohji K; Katsuoka Y; Okamoto M; Kamidono S; Kitazawa S; Toyoshima M; Dong J; Nakajima M
Hinyokika Kiyo; 2000 Oct; 46(10):757-62. PubMed ID: 11215206
[TBL] [Abstract][Full Text] [Related]
30. Coexpression of heparanase, basic fibroblast growth factor and vascular endothelial growth factor in human esophageal carcinomas.
Mikami S; Ohashi K; Katsube K; Nemoto T; Nakajima M; Okada Y
Pathol Int; 2004 Aug; 54(8):556-63. PubMed ID: 15260846
[TBL] [Abstract][Full Text] [Related]
31. Heparanase activity in cultured endothelial cells.
Godder K; Vlodavsky I; Eldor A; Weksler BB; Haimovitz-Freidman A; Fuks Z
J Cell Physiol; 1991 Aug; 148(2):274-80. PubMed ID: 1880155
[TBL] [Abstract][Full Text] [Related]
32. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
33. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
34. Immunomodulatory Activities of the Heparan Sulfate Mimetic PG545.
Bendersky V; Yang Y; Brennan TV
Adv Exp Med Biol; 2020; 1221():461-470. PubMed ID: 32274722
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky I; Mohsen M; Lider O; Svahn CM; Ekre HP; Vigoda M; Ishai-Michaeli R; Peretz T
Invasion Metastasis; 1994-1995; 14(1-6):290-302. PubMed ID: 7657522
[TBL] [Abstract][Full Text] [Related]
37. The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo.
Burns CJ; Fantino E; Powell AK; Shnyder SD; Cooper PA; Nelson S; Christophi C; Malcontenti-Wilson C; Dubljevic V; Harte MF; Joffe M; Phillips ID; Segal D; Wilks AF; Smith GD
J Pharmacol Exp Ther; 2011 Dec; 339(3):799-806. PubMed ID: 21917561
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of angiogenesis involves in anticancer activity of riccardin D, a macrocyclic bisbibenzyl, in human lung carcinoma.
Sun CC; Zhang YS; Xue X; Cheng YN; Liu HP; Zhao CR; Lou HX; Qu XJ
Eur J Pharmacol; 2011 Sep; 667(1-3):136-43. PubMed ID: 21704029
[TBL] [Abstract][Full Text] [Related]
39. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
40. LYP, a bestatin dimethylaminoethyl ester, inhibited cancer angiogenesis both in vitro and in vivo.
Gao JJ; Xue X; Gao ZH; Cui SX; Cheng YN; Xu WF; Tang W; Qu XJ
Microvasc Res; 2011 Sep; 82(2):122-30. PubMed ID: 21664364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
